Abiomed (ABMD) Tops Q3 EPS by 22c, Offers Q4 Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Abiomed (ABMD) Tops Q3 EPS by 22c, Offers Q4 Guidance

Abiomed Announces Q3 FY 2021 Record Revenue of $232 Million, up 5% Year Over Year, With 31% Operating Margin

January 28, 2021 7:00 AM EST

DANVERS, Mass.--(BUSINESS WIRE)-- Abiomed, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies today reported record revenue in the third quarter fiscal 2021 of $231.7 million, a year over year increase of 5% compared to Q3 fiscal year 2020 despite the negative impact of COVID-19. Operating income was $71.4 million up 2%, compared to $70.3 million in the same period of fiscal 2020.

Recent financial and operating highlights include:

Worldwide Impella® product revenue for the quarter totaled $220.8 million, an increase of 4% compared to revenue of $212.6 million during Q3 fiscal year... More